We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Non-Invasive AI-Powered Urine Test Enables Early Bladder Cancer Detection

By LabMedica International staff writers
Posted on 26 Nov 2024

Urothelial carcinoma, the most common type of bladder cancer, ranks among the top 10 most prevalent cancers globally, with an estimated 573,278 new cases and 212,536 deaths in 2020. More...

The absence of specific symptoms and the high recurrence rate make diagnosing and monitoring urothelial carcinoma particularly challenging for the urology community. Early detection and timely monitoring of postoperative recurrence can significantly enhance survival rates and the quality of life for patients with this type of cancer. Current diagnostic guidelines recommend a combination of cystoscopy and voided urine cytology. While cystoscopy is considered the gold standard, it is an invasive, uncomfortable procedure that carries risks of infection, trauma, and high costs. Additionally, the sensitivity (ranging from 68% to 84%) and specificity (31% to 93%) of standard white light cystoscopy are not ideal.

Urine cytology remains the preferred noninvasive method for detecting urothelial carcinoma. However, despite its good specificity, its sensitivity is inadequate, especially for low-grade and low-stage tumors. A review of 26 studies found that the median sensitivity and specificity of urine cytology for urothelial carcinoma surveillance were 35% and 94%, respectively. As a result, existing methods for diagnosing and monitoring bladder cancer are either invasive or lack sufficient sensitivity and specificity. There is an urgent clinical need for an accurate, noninvasive detection method for bladder cancer. Now, a multi-gene diagnostic test offers an advanced solution for diagnosing and monitoring the recurrence of urothelial carcinoma.

The UriBLAD test by Canhelp Genomics (Hangzhou, China) is a non-invasive urine test designed for early detection and recurrence monitoring of bladder cancer. This test uses an 8-gene expression assay combined with artificial intelligence (AI) analysis software to facilitate non-invasive detection when used alongside other clinical assessments. By utilizing real-time quantitative PCR technology, UriBLAD measures the expression levels of eight key genes associated with urothelial carcinoma in urine. The AI algorithms then help distinguish urothelial carcinoma, aiding in diagnosis and monitoring for recurrence.

Unlike cystoscopy, UriBLAD is a non-invasive, painless alternative that improves detection rates of early-stage and low-grade bladder cancer, offering better prognosis prospects for patients. By reducing patient anxiety, it encourages more frequent check-ups, especially for those who need regular surveillance following surgery. Simple to administer for both patients and healthcare providers, UriBLAD provides clinicians with additional diagnostic insights to support further treatment decisions. The test has shown high specificity and sensitivity across all tumor types, with an accuracy of 89.9%, sensitivity of 82.6%, and specificity of 95.1%.

Related Links:
Canhelp Genomics


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.